Minimally invasive glaucoma surgery—known as MIGS—is an evolving method to lower intraocular pressure with minimal impact on the eye’s surface. This approach involves small, targeted procedures using devices like the Hydrus, iStent, or iStent inject. The treatment improves fluid drainage through a tiny incision at the iridocorneal angle, making it especially suitable for eyes with open-angle glaucoma or ocular hypertension.
Procedure summary
How It’s Performed
A miniature device is inserted into Schlemm’s canal via a tiny corneal incision.
Device Options
- Hydrus: A flexible Nitinol implant that opens and scaffolds the canal.
- iStent: A small heparin-coated titanium snorkel-like stent.
- iStent inject: Even smaller than the iStent, typically implanted as two devices for enhanced drainage.
Safety Note
These implants are MRI-safe, ensuring compatibility with routine imaging.
Clinical benefits
- Quickly reduces eye pressure with minimally invasive technique
- Delivers a strong safety profile—ideal for earlier-stage glaucoma
- Often performed alongside cataract surgery, offering efficient dual treatment
- Reduces dependence on glaucoma medications, improving quality of life
